Merck, Eli Lilly Covid-19 Treatments Power Quarterly Sales Gains
CFO News Room
FEBRUARY 3, 2022
Merck’s newly authorized molnupiravir treatment logged sales of $952 million in the fourth quarter, the first period when the drug contributed revenue. Meanwhile, sales of Covid-19 antibodies for Lilly grew by 22% year over year to $1.06 Sales of Covid-19 antibodies for Lilly grew by 22% year over year to $1.06 a share to $8.65
Let's personalize your content